The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Advancing treatments in leukemia are transforming patient outcomes
Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the recent advancements in leukemia treatment that have transformed patient outcomes. The use of BCR-ABL tyrosine kinase inhibitors has revolutionized chronic myeloid leukemia treatment paradigm, as has ibrutinib plus venetoclax combination therapy in chronic lymphocytic leukemia. Combining chemotherapy with targeted agents has proved an effective approach in acute myeloid leukemia and acute lymphoblastic leukemia where response rates and survival are better than ever before. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
